Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
|Videos|April 29, 2019
JAK Inhibition for the Management of Primary Myelofibrosis
JAK Inhibition for the Management of Primary Myelofibrosis
Advertisement
Case: 66-Year-Old Man Diagnosed With Primary Myelofibrosis
January 2019
- A 66-year old man presents to primary care physician with complaints of fatigue, headache, and abdominal discomfort when taking deep breaths
- PMH: depression
- PE: Splenomegaly ~7 cm below left costal margin
- Lab values:
- HGB: 9.2 g/dL
- Platelets: 242 x 109/L
- WBC: 26.2 x 109/L
- Serum LDH: 1400 U/L
- Serum EPO: 10.9 mU/mL
- Bone Marrow Biopsy:
- MF-3
- Circulating blasts, 1.1%
- JAK V617Fmutation; trisomy 8
- Peripheral Blood Smear: leukoerythroblastosis
- Diagnosis: Primary myelofibrosis
Advertisement
Related to this article
Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.
Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate in a real-world NET analysis.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Advertisement
Advertisement
Trending on Targeted Onc
1
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
2
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
3
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
4
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
5